{"id":"piperacillin-tazobactam-intermittent-infusion","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Diarrhea"},{"rate":"3-7%","effect":"Nausea"},{"rate":"1-3%","effect":"Vomiting"},{"rate":"2-4%","effect":"Rash"},{"rate":"2-5%","effect":"Phlebitis at infusion site"},{"rate":"1-3%","effect":"Headache"},{"rate":"0.1-1%","effect":"Allergic reactions/anaphylaxis"},{"rate":"0.5-2%","effect":"Clostridioides difficile infection"}]},"_chembl":null,"_fixedAt":"2026-03-30T11:55:45.257088","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piperacillin is an extended-spectrum penicillin that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking, leading to cell lysis and death. Tazobactam is a beta-lactamase inhibitor that irreversibly binds to and inactivates bacterial beta-lactamases, preventing enzymatic degradation of piperacillin and extending its spectrum to include beta-lactamase-producing organisms. The intermittent infusion formulation delivers the combination intravenously over 20-30 minutes at regular intervals.","oneSentence":"Piperacillin/tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:01.678Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections caused by susceptible organisms including Gram-negative and Gram-positive aerobic bacteria and anaerobes"},{"name":"Hospital-acquired and community-acquired pneumonia"},{"name":"Intra-abdominal infections"},{"name":"Urinary tract infections"},{"name":"Skin and soft tissue infections"},{"name":"Febrile neutropenia"}]},"_fixedFields":["pubmed(61)"],"trialDetails":[{"nctId":"NCT07484633","phase":"PHASE4","title":"A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","startDate":"2026-04","conditions":"Infection, Sepsis, NICU","enrollment":110},{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":"Acute Kidney Injury","enrollment":750},{"nctId":"NCT06184659","phase":"PHASE4","title":"Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis","status":"RECRUITING","sponsor":"Scandinavian Critical Care Trials Group","startDate":"2025-06-26","conditions":"Sepsis, Septic Shock","enrollment":5800},{"nctId":"NCT05102162","phase":"PHASE4","title":"BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia","status":"TERMINATED","sponsor":"University of Florida","startDate":"2021-12-17","conditions":"Pneumonia","enrollment":35},{"nctId":"NCT03108690","phase":"PHASE4","title":"Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia","status":"WITHDRAWN","sponsor":"Sara Thønnings","startDate":"2017-10-01","conditions":"Bacteremia","enrollment":""},{"nctId":"NCT01694069","phase":"PHASE4","title":"Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":6},{"nctId":"NCT03019965","phase":"NA","title":"Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2017-02-01","conditions":"Sepsis","enrollment":426},{"nctId":"NCT04895657","phase":"PHASE4","title":"Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-07-27","conditions":"Gram-Negative Infections","enrollment":56},{"nctId":"NCT04233996","phase":"PHASE4","title":"Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2019-06-05","conditions":"Febrile Neutropenia","enrollment":150},{"nctId":"NCT01667094","phase":"PHASE4","title":"A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis","status":"UNKNOWN","sponsor":"The Alfred","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":50},{"nctId":"NCT01796717","phase":"PHASE2, PHASE3","title":"Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-03","conditions":"Nosocomial Pneumonia","enrollment":50},{"nctId":"NCT01577368","phase":"PHASE3","title":"Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2011-05","conditions":"Pseudomonas Aeruginosa Infection","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"recentPublications":[{"date":"2026 Feb","pmid":"41322102","title":"Continuous versus intermittent beta-lactam antibiotic infusions in critically ill patients: The UK cohort of the BLING III trial.","journal":"Journal of the Intensive Care Society"},{"date":"2024 Jun","pmid":"39493742","title":"Continuous versus intermittent infusion of beta-lactam antibiotics: where do we stand today? A narrative review.","journal":"Germs"},{"date":"2025 Feb","pmid":"39433124","title":"Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial.","journal":"Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"date":"2024 Aug 27","pmid":"38864155","title":"Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.","journal":"JAMA"},{"date":"2024 Feb 1","pmid":"38018847","title":"A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia.","journal":"Therapeutic drug monitoring"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Piprataz injection"],"phase":"marketed","status":"active","brandName":"Piperacillin/Tazobactam Intermittent infusion","genericName":"Piperacillin/Tazobactam Intermittent infusion","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piperacillin/tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation. Used for Bacterial infections caused by susceptible organisms including Gram-negative and Gram-positive aerobic bacteria and anaerobes, Hospital-acquired and community-acquired pneumonia, Intra-abdominal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}